Blanket Purchase Agreement 36F79724D0026-36E79725A0014
Award Date
4/10/25
Last Date to Order
4/9/26
Federal Agency
National Acquisition Center
Awardee
Immunocore Commercial LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The U.S. Department of Veterans Affairs (VA) has awarded Immunocore Commercial LLC, a foreign-owned, for-profit manufacturer of goods, a Federal Supply Schedule (FSS) Indefinite Delivery Vehicle (IDV) contract (ID: 36F79724D0026) with a $225,000 ceiling value. This multiple-award IDV, which runs through November 14, 2028, covers Federal Supply Classification 65 I B, encompassing drugs, pharmaceuticals, and hematology-related products.
Immunocore Commercial LLC has received multiple firm...
The Federal Supply Schedule (FSS) contract 36F79723D035E awarded to Immunocore Commercial LLC by the U.S. Department of Veterans Affairs (VA) is an interim agreement focused on delivering drugs, pharmaceuticals, and hematology-related products under Federal Supply Classification 65 I B. The $25,000 ceiling value contract has an ultimate completion date of November 14, 2023.
Immunocore Commercial LLC, a foreign-owned for-profit manufacturer of goods, has been consistently awarded delivery...
This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the U.S. Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The BPA, valued at $21.5 million, is under Novartis' $5.4 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), which runs through August 2025. The purpose of the BPA is to facilitate the VA's procurement of Kymriah, Novartis'...
This Federal Supply Schedule contract was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 to Immunomedics, Inc. The contract falls under the Pharmaceuticals and Drugs (FSS-61-IB) Master GSA Schedule, with a potential value of $10,000,000. The period of performance is January 1, 2021 through December 31, 2025.
The contract aims to procure drugs, pharmaceuticals, and hematology-related products for the VA network through task...
The federal contract IDV award is for a Federal Supply Schedule (FSS) contract with the Department of Veterans Affairs (VA) for "65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS." The prime contractor is Kamada Inc., a foreign-owned for-profit organization.
The contract has a ceiling value of $750,000.00 and a period of performance from July 1, 2024 to June 30, 2029. The contract was awarded without any set-asides and is a multiple award. As an FSS contract, it...
This federal contract IDV is an interim agreement awarded under Federal Supply Schedule (FSS) 65 IB, which covers drugs, pharmaceuticals, and hematology-related products. The contract was awarded by the Veterans Integrated Service Network 12, a civilian agency of the U.S. federal government, to Immunogen Inc., a for-profit organization, on December 16, 2022. The contract has a ceiling value of $25,000.00 and an ultimate completion date of June 14, 2023.
The purpose of this contract is to...
The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Provention Bio Inc. to provide the pharmaceutical product TZIELD. The $5 million BPA has a period of performance through June 2024 and is one of two BPAs awarded against Provention Bio's existing $5 million Federal Supply Schedule 65 I B contract, which was initially awarded in July 2023 for a 5-year term. An additional $1.44 million BPA was...
The National Acquisition Center, a civilian agency within the U.S. Department of Veterans Affairs (VA), has awarded a $31,375,000 Blanket Purchase Agreement (BPA) to Horizon Therapeutics USA, Inc. This single-award IDV contract is established against the GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and covers the procurement of several specialty medications, including Ravicti, Buphenyl, Krystexxa, Procysbi, and Uplizna. The BPA, effective from September 2024 through September 2025,...
The provided information describes a Blanket Purchase Agreement (BPA) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders.
The single-award BPA (Contract #36E79724A0005) has a ceiling value of $5,500,000 and is effective from January 18, 2024 to September 19, 2024. It was awarded without the use of a set-aside and enables the...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used.
The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...